XML 56 R44.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of the Net Purchase Price and Allocation to the Acquired Assets (Detail) - ProstaGene, LLC - USD ($)
3 Months Ended
Aug. 31, 2020
May 31, 2020
Business Acquisition, Contingent Consideration [Line Items]    
CytoDyn Inc. equity $ 11,558,000  
Acquisition expenses 741,000  
Release of deferred tax asset 2,827,000  
Total cost of acquisition 15,126,000  
Intangible assets 15,126,000 $ 15,126,000
Other 0  
Allocation of acquisition costs $ 15,126,000